Avicanna Secures US Patent For Topical Cannabinoid Technology To Treat Pain And Inflammation
Avicanna Inc. (OTCQX:AVCNF), a leading biopharmaceutical company specializing in plant-derived cannabinoid-based products, has announced the issuance of U.S. Patent No. US 20230025693A1 by the United States Patent and Trademark Office (USPTO). This patent covers Avicanna’s deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.
“We are very happy with the issuance of another USPTO patent, this time on transdermal topical technology that has been a significant part of our research & development, R&D and clinical efforts,” stated Aras Azadian, CEO of Avicanna. “This technology was created through years of development, including AI-guided prediction modeling, pre-clinical trials and real-world evidence, and …